Tilaxin, 125 mg 10 pcs

ATX:

L.03.A.X Other immunostimulants

Pharmacodynamics:

A low molecular weight synthetic interferon inducer that stimulates formation of interferon alpha, beta and gamma in the body. The main producers of interferon in response to tiloron administration are intestinal epithelial cells, hepatocytes, T lymphocytes, neutrophils and granulocytes. After oral administration, the maximum production of interferon is determined in the sequence intestine – liver – blood in 4-24 hours. Amixin® has an immunomodulatory and antiviral effect.

In human leukocytes it induces synthesis of interferon. It stimulates bone marrow stem cells and, depending on the dose, enhances antibody formation, reduces the degree of immunosuppression, restores the ratio of T-suppressors and T-helpers. Effective against various viral infections, including influenza viruses, other acute respiratory viral infections, hepatitis viruses and herpesviruses. The mechanism of antiviral action is associated with inhibition of translation of virus specific proteins in infected cells resulting in suppression of virus reproduction.

Pharmacokinetics:

After oral administration, it is rapidly absorbed from the gastrointestinal tract. Bioavailability is 60%. About 80% of the drug is bound to plasma proteins. The drug is excreted practically unchanged in intestine (70%) and kidney (9%). The elimination half-life (T1/2) is 48 hours. The drug is not biotransformed and does not accumulate in the body.

Indications

Active ingredient

Composition

Composition (1 tablet):

How to take, the dosage

Internal, after meals. Dose, frequency of administration and duration of treatment are determined individually depending on indications; average single dose for adults is 0.125-0.25 g, for children over 7 years – 0.06 g.

In the treatment of influenza and other acute respiratory infections: adults – in the first two days of the disease 0.125 g, then – 0.125 g in 48 hours. The course dose is 0.75 g. For prophylaxis of flu and other acute respiratory viral infections: 0.125 g once a week during 6 weeks.

In children over 7 years old in case of uncomplicated forms of flu or other ARI – 0.06 g 1 time per day during the 1st, 2nd and 4th days after the treatment start (for the course of treatment 0.18 g – 3 tablets).

In case of complications of influenza or other acute respiratory viral diseases the preparation is taken on the 1st, 2nd, 4th and 6th day after the treatment start (for the course of treatment 0.24 g – 4 tablets).

Interaction

Tiloron is compatible with antibiotics, traditional treatments for viral and bacterial diseases.

Special Instructions

It is not recommended to use tiloron in doses higher than recommended in order to avoid possible short-term depletion of immunocompetent cells.

Tiloron is used as part of complex therapy of neuroviral infections under medical supervision.

Contraindications

Pregnancy, lactation (breastfeeding), children under 7 years of age, hypersensitivity to tiloron.

Side effects

Possible: transient chills, allergic reactions.

In isolated cases: dyspeptic symptoms.

Similarities